# A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

> **NCT00096603** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 450 (—)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Raptiva (efalizumab)

## Key facts

- **NCT ID:** NCT00096603
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2004-07
- **Target enrollment:** 450 (—)
- **Last updated:** 2014-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096603, "A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00096603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*